News for BTTX Stock

Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023 Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023 Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates Better Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 Better Therapeutics Announces $6.5MM Private Placement Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Better Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023 Better Therapeutics to Participate in Two Upcoming Investor Conferences Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Better Therapeutics to Participate in BTIG Digital Health Forum Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates Better Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022 Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer Positive Results from Pivotal Trial of Better Therapeutics’ Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care Better Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes Better Therapeutics to Participate in Three Upcoming Investor Conferences Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Better Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022 Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes Better Therapeutics Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001, a Novel Prescription Digital Therapy, in Clinical Cardiology Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference Better Therapeutics to Participate in Cowen’s Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022 Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform Better Therapeutics Appoints Frank Karbe as Chief Executive Officer Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabetes Association Guidelines Recommending Digital Tools in Diabetes Care Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones Better Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 13, 2022 Better Therapeutics Announces Key Milestones and Updates for Ongoing Studies of its Digital Therapeutics Approach for Cardiometabolic Diseases Better Therapeutics to Participate in Chardan’s Virtual Prescription Digital Therapeutics Summit Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results Better Therapeutics to Host Call Detailing Promising Results from Pivotal Clinical Trial for Type 2 Diabetes Digital Therapeutics Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes Better Therapeutics Sponsors Educational Symposium on the Use of Software as a Next-Generation Treatment for Cardiometabolic Diseases Better Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies (PDTs) Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research Better Therapeutics to Participate in Two Upcoming Investor Events Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022 Better Therapeutics Appoints Deepti Sodhi Jaggi, PharmD, as Chief Strategy Officer Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes Better Therapeutics Appoints Thiago Licias de Oliveira as Its Chief People Officer Mass General Brigham Joins Better Therapeutics in Real World Evidence Study Collaboration Better Therapeutics Closes Business Combination and Debuts on Nasdaq